Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the clinical efficacy and safety of a combination of afatinib and bevacizumab after AR. METHODS: Patients with EGFR-mutant non-small cell lung cancer after AR were enrolled during any line of therapy. Afatinib was prescribed at 30 mg, and 15 mg/kg bevacizumab was administered every 3 weeks until progression. RESULTS: Between October 2014 and May 2017, 32 eligible patients were evaluated. The mutation subtypes were ), L858R (11 [34%]), and L861Q (1 [3%]). T790M was detected in 14 patients (44%). The median number of prior regimens was 4 (range, 1-10). Six patients obtained a partial response, and 23 had stable disease; this resulted in an objective response rate (ORR) of 18.8% (95% confidence interval [CI], 7.2%-36.4%) and a disease control rate of 90.7% (95% CI, 75.0%-98.0%). The median progression-free survival (PFS) was 6.3 months (95% CI, 3.9-8.7 months). The ORRs and median PFS times of T790M+ and T790M-patients were 14.3% and 22.2%, respectively, and 6.3 and 7.1 months, respectively; those of Del-19 and L858R patients were 20.0% and 11.1%, respectively, and 6.3 and 5.1 months, respectively. Grade 3 or higher adverse events (incidence ≥ 10%) included paronychia (25%), hypertension (41%), and proteinuria (19%). There were no treatment-related deaths, interstitial lung disease, or bevacizumab-associated severe bleeding. CONCLUSIONS: Afatinib plus bevacizumab demonstrated clinical efficacy and safety after AR to EGFR TKIs and could be a therapeutic salvage option for T790M-populations.Cancer 2018;124:3830-3838.
INTRODUCTION
Lung cancer is a leading cause of cancer deaths worldwide, and non-small cell lung cancer (NSCLC) is the primary histological type of lung cancer. Unfortunately, most patients reveal already metastatic disease at their initial diagnosis, and this results in an incurable situation. The standard therapeutic option for metastatic NSCLC was once cytotoxic chemotherapies, but the improvement of those therapies has reached its limit. Molecular-targeted therapies are currently being developed for specific genetic alterations such as epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase gene fusions. [1] [2] [3] First-line EGFR TKIs have proven to be more effective than platinum doublets for patients with EGFR-sensitive mutations according to prospective randomized phase 3 trials. 4 Most patients exhibited an early dramatic response before finally developing acquired resistance (AR). Among several mechanisms of AR to EGFR TKIs, [5] [6] [7] [8] the gatekeeper EGFR mutation, a threonine-to-methionine substitution at amino acid position
Cancer October 1, 2018 790 in exon 20 (T790M), is the most common mechanism, and it is found in more than half of cases of AR to EGFR TKIs. 9 Therefore, it is clinically important to develop more effective therapies for patients with T790M. Indeed, osimertinib, a third-generation EGFR TKI, has exhibited effectiveness for T790M+ populations. 10 A randomized phase 3 trial comparing osimertinib with platinum doublets for T790M+ patients after first-line EGFR TKI failure showed that osimertinib resulted in significantly longer progression-free survival (PFS) than platinum doublets. 11 According to that evidence, osimertinib is now established as a standard therapy for T790M+ patients after classic EGFR TKI failure. On the other hand, there are almost no effective therapeutic options for targeted molecular therapies in T790M-populations, and cytotoxic chemotherapies are still administered to those patients.
Afatinib, an irreversible ErbB family blocker, showed preclinical effectiveness against many EGFR-mutant cell lines, including those with T790M. 12, 13 Although those preclinical studies led us to expect that afatinib would overcome AR to EGFR TKIs, irreversible EGFR TKI monotherapies such as afatinib and dacomitinib actually exhibited only moderate clinical efficacy after AR to reversible EGFR TKIs. [14] [15] [16] Bevacizumab is a recombinant, humanized monoclonal antibody directed against vascular endothelial growth factor, a key element in tumor-associated angiogenesis. The addition of bevacizumab to carboplatin plus paclitaxel has shown a survival benefit in frontline settings of metastatic nonsquamous NSCLC in a randomized phase 3 trial. 17 In addition, EGFR TKIbevacizumab combination therapy has shown promising efficacy for chemotherapy-naive patients with EGFRmutant NSCLC in recent clinical trials. 18, 19 Some preclinical studies using TKI-resistant models also found that the addition of bevacizumab to EGFR TKI treatment resulted in synergistic effects. 20, 21 Furthermore, the addition of bevacizumab to afatinib treatment demonstrated strong synergistic effects in TKI-resistant xenograft models. 22 Thus, a number of previous studies have suggested that the addition of bevacizumab to EGFR TKI treatments may overcome AR.
We hypothesized that afatinib-bevacizumab combination therapy could overcome clinical AR to EGFR TKIs. The aim of this study was to evaluate the clinical efficacy and safety of afatinib-bevacizumab combination therapy in EGFR-mutant NSCLC after AR to EGFR TKIs.
MATERIALS AND METHODS

Study Design
This ABC (Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR TKIs in EGFRMutant Non-Small Cell Lung Cancer) study was a prospective, multicenter, single-arm, open-label, phase 2 trial conducted by the HANSHIN Oncology Group to evaluate the clinical efficacy and safety of afatinibbevacizumab combination therapy after AR in EGFRmutant NSCLC. The primary endpoint was the objective response rate (ORR), which was determined by an independent review according to the Response Evaluation Criteria in Solid Tumors (version 1.1). The secondary endpoints were PFS, overall survival (OS), disease control rate (DCR), and safety. The study was conducted in accordance with the Declaration of Helsinki with the approval of each institutional review board. All patients provided written informed consent before study participation. The study was registered under a University Hospital Medical Information Network (UMIN) Clinical Trials Registry identifier (UMIN 000014710).
Study Population
Patients were diagnosed with cytologically or histologically confirmed EGFR-mutant NSCLC with AR to EGFR TKIs (according to Jackman et al's criteria 23 ). Rebiopsy after AR was essential before enrollment to confirm the T790M status. The T790M status was examined with relatively sensitive polymerase chain reaction (PCR) methods such as the peptide nucleic acidlocked nucleic acid PCR clamp, the mutation-biased PCR quenching probe method, and Cobas. 24, 25 Patients were at least 20 years old, had an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2, and had a life expectancy of at least 3 months. The patients had to have adequate organ function with at least 1 tumor lesion measurable by computed tomography. All patients were eligible after any lines of therapy (second line or later).
Thoracic radiotherapy was not allowed within the 4 weeks before enrollment, nor were any extrathoracic radiotherapies allowed within the week before enrollment. Patients were excluded if they had interstitial lung disease, gastrointestinal disorders with severe symptomatic diarrhea, significant cardiovascular disease, serious drug hypersensitivity, coelomic fluid retention, uncontrolled concomitant diseases, inadequate baseline organ function, additional significant malignancies diagnosed within the past 5 years, or symptomatic brain metastases.
Patients with a contraindication for bevacizumab use, such as squamous histology, a history of massive hemoptysis, or tumor invasion to a major vessel/bronchus, were ineligible. A prior treatment history with an EGFR TKI plus bevacizumab was not permitted.
Treatment
Oral afatinib was prescribed at an initial dosage of 30 mg once daily 1 hour before food until progressive disease, withdrawal of consent, or withdrawal due to adverse events (AEs). Afatinib was stopped for up to 14 days when patients suffered from any grade 3 or higher drug-related AE according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0) or from grade 2 diarrhea, nausea, or vomiting for 7 or more consecutive days despite adequate supportive care. After the patients recovered to a grade 1 or higher AE or the baseline (whichever was higher), afatinib was re-administered at a reduced dose of 20 mg. Afatinib was discontinued if there was a second occurrence of an AE. Dose escalations of afatinib from 30 to 40 mg were permitted when all AEs remained within grade 1.
Bevacizumab was administered at a dosage of 15 mg/ kg once every 3 weeks until progression. Bevacizumab was interrupted if there was pulmonary hemorrhage of any grade, grade 2 or higher extralung hemorrhage, grade 3 or higher proteinuria, or uncontrolled hypertension.
After the termination of each drug, continuous afatinib or bevacizumab monotherapy was allowed.
The treatment of tumor-related symptoms and AEs by medications such as antidiarrheals, antibiotics, analgesics, and antiemetics was permitted.
Efficacy and Safety Assessments
Baseline tumor assessments used computed tomography or magnetic resonance imaging scans of at least 1 lesion at the initial screening. ORR was measured via the monitoring of the same target lesions 6, 12, and 18 weeks after the initial treatment and then every 8 to 12 weeks thereafter until study termination. Patients were assigned on the basis of their best response to 1 of the following Response Evaluation Criteria in Solid Tumors categories: complete response, partial response, stable disease, or progressive disease. Patients experiencing a complete response or partial response lasting for more than 4 weeks were included in the ORR, whereas those experiencing stable disease after at least 6 weeks in the study were considered to have achieved disease control.
AEs defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0) were evaluated during and after the study treatment period.
Statistical Analyses
Previous prospective studies evaluating afatinib monotherapy after the failure of first-generation EGFR TKIs showed ORRs of 7% and 8.2%. 14, 15 Our study would have included many heavily pretreated patients, so we set the threshold ORR to 5% and the expected ORR to 25%. On the basis of that assumption, the number of patients needed to provide 80% power for a 1-sided .05 level of type I error was calculated to be 28. Taking the possibility of ineligible patients into account, we set the sample size at 32. PFS and OS curves and 95% confidence intervals (CIs) were estimated with the KaplanMeier method. Preplanned subgroup analyses were performed for the T790M status (positive vs negative), EGFR mutation type (Del-19 vs L858R), bevacizumab use (naive vs rechallenge/beyond progression), and TKIfree interval (none vs interval with cytotoxic regimens). The ORRs and PFSs were compared with the chi-square test and the log-rank test, respectively. A P value less than .05 (1-sided) was considered significant for the primary endpoint, ORR. The statistical analyses were performed with JMP 12 (SAS Institute, Inc, Cary, North Carolina).
RESULTS
Patients
Thirty-four patients were enrolled between October 2014 and September 2016. On the basis of the safety results from the initial 6 enrolled patients, the investigators and an independent data monitoring committee decided to exclude patients with a PS of 2 and those with symptomatic central nervous system metastases from proceeding further in the trial. Two patients were ineligible because they had no measurable lesions and a PS of 3. We finally evaluated a total of 32 patients by May 2017. The baseline characteristics are shown in Table 1 . The median age was 66 years (range, 48-86 years). A PS of 0/1 was dominant except for 1 patient with a PS of 2 who had been enrolled before the decision to exclude patients with a PS of 2. The frequencies of the mutation subtypes were as follows: Del-19, 20 (63%); L858R, 11 (34%); and L861Q, 1 (3%). T790M was detected in 14 patients (44%). The median number of prior regimens was 4 (range, 1-10). Afatinib and bevacizumab were directly Cancer October 1, 2018 initiated after prior EGFR TKIs without intervals with cytotoxic chemotherapies in 23 patients (72%). Eighteen patients (56%) were bevacizumab-naive.
Drug Delivery
The afatinib dose was reduced to 20 mg in 17 patients (53%). The reasons for dose reductions were paronychia (grade 3; n = 5), diarrhea (grade 2/3; n = 3), rash (grade 2/3; n = 2), mucositis (grade 2/3; n = 2), doctor's discretion (n = 3), and patient's request (n = 2). Afatinib therapy was terminated without progression or death in 2 patients (6%) because of intolerable afatinib-related AEs (grade 2 diarrhea and grade 3 anorexia). Afatinib was interrupted in 16 patients (50%) and increased to 40 mg in 2 patients (6%).
The median number of bevacizumab administrations was 6 (range, 2-14). Bevacizumab administration was interrupted in 6 patients (19%) because of proteinuria (grade 2/3).
Efficacy
Waterfall plots showed a tumor change from the baseline in each patient (Fig. 1) . Six patients obtained a confirmed partial response, and 23 achieved stable disease; this resulted in an ORR of 18.8% (90% CI, 8.5%-33.7%; 95% CI, 7.2%-36.4%) and a DCR of 90.7% (95% CI, 75.0%-98.0%; Table 2 ). The lower limit of the 2-sided 90% CI (ie, the 1-sided 95% CI) of the ORR was 8.5%, which was over the threshold of a 5% ORR and indicated a statistically significant, positive result.
The median follow-up was 12.8 months (range, 2.6-29.5 months) for all eligible patients. The median PFS and OS were 6.3 months (95% CI, 3.9-8.7 months) and not reached, respectively (Fig. 2) .
Subgroup Analyses
We compared ORRs and PFS times between the T790M+ (n = 14) and T790M-populations (n = 18). The ORRs and median PFS times of the T790M+ patients and the T790M-patients were 14.3% and 22.2% (P = .2094), respectively, and 6.3 months (95% CI, 3.5-9.5 months) Cancer October 1, 2018 and 7.1 months (95% CI, 2.8-9.3 months; P = .7910), respectively (Fig. 3) .
We also compared Del-19 (n = 20) and L858R (n = 11), excluding 1 patient with L861Q. The ORRs and median PFS times of the patients with Del-19 and the patients with L858R were 20.0% and 11.1% (P = .9024), respectively, and 6.3 months (95% CI, 2.8-7.8 months) and 5.1 months (95% CI, 2.9-9.3 months; P = .7777), respectively (Fig. 4) .
Efficacies were analyzed with respect to prior bevacizumab exposure (naive [n = 18] vs rechallenge/beyond progression [n = 14]) and TKI-free intervals (none [n = 23] vs an interval with cytotoxic regimens [n = 9]). The
ORRs and median PFS times of bevacizumab-naive and beyond-progression/rechallenged patients were 17% and 21% (P = .7321), respectively, and 4.0 months (95% CI, 2.8-10.3 months) and 7.1 months (95% CI, 2.9-9.1 months; P = .9834), respectively. The ORRs and median PFS times of patients with no TKI-free interval and patients with an interval with cytotoxic regimens were 22% and 11% (P = .1567), respectively, and 5.8 months (95% CI, 3.4-9.1 months) and 7.8 months (95% CI, 2.8-10.1 months; P = .8154), respectively. Table 3 shows the treatment-related AEs that had a frequency ≥ 10%. There was no grade 2 or higher liver dysfunction. Afatinib-related AEs such as rash (90.6%) and diarrhea (90.6%) were frequently observed. Grade 3 or higher AEs (incidence ≥ 10%: paronychia [25%], hypertension [41%], and proteinuria [19%]) were confirmed without grade 4 AEs. There were no treatment-related deaths, interstitial lung disease, or bevacizumabassociated severe bleeding.
Safety
DISCUSSION
Our study has demonstrated the clinical efficacy and safety of afatinib-bevacizumab combination therapy after Cancer October 1, 2018 AR to EGFR TKIs. The ORR was 18.8%. The lower limit of the 2-sided 95% CI (7.2%) and that of the 2-sided 90% CI (8.5%) were higher than the threshold ORR of 5%, and this indicated a statistically significant, positive result for the primary endpoint. That result suggests that afatinib-bevacizumab combination therapy overcame AR to EGFR TKIs in some of the patients. The ORR appears to be relatively low, but waterfall plots showed that most patients achieved some tumor shrinkage. Moreover, the DCR was more than 90%, and the median PFS was 6.3 months (95% CI, 3.9-8.7 months). Our study included many heavily pretreated patients (median number of prior regimens, 4; range, 1-10). The treatment purpose in such patients was not tumor shrinkage but rather was extended survival without intolerable toxicities. Thus, afatinib-bevacizumab combination therapy could provide longer disease control without intolerable toxicities in pretreated patients after AR to EGFR TKIs. The ORR and median PFS of the T790M-population were 22.2% and 7.1 months, respectively. In the T790M+ population, osimertinib is the standard therapy and should be prescribed before other regimens.
Osimertinib has shown ORRs of 60% to 70% and median PFS times of 10 to 11 months for T790M+ patients. 10, 11 On the other hand, there are few therapeutic options for T790M-patients. The median PFS of 7.1 months is comparable to that achieved with platinum-doublet cytotoxic chemotherapy regimens after the failure of first-line EGFR TKIs. 26 Therefore, afatinib-bevacizumab combination therapy could be a therapeutic salvage option for T790M-patients.
In the T790M+ population, the ORR and median PFS were 14.3% and 6.3 months, respectively. As mentioned previously, osimertinib is the standard therapy for T790M+ patients. However, the results of afatinibbevacizumab combination therapy might be better than those of other cytotoxic or rechallenge EGFR TKI monotherapies. [27] [28] [29] [30] Notably, only 1 patient received afatinib-bevacizumab combination therapy after osimertinib failure. The patient achieved a minor response with 6-month PFS. Moreover, C797S (trans), human epidermal growth factor receptor 2 amplification, and minor mutations such as E709K, L718Q, and L844V have been reported as mechanisms of resistance to Abbreviations: ALT, aspartate aminotransferase; AST, aspartate transaminase; CRE, creatinine.
There were no grade 4 or higher adverse events, interstitial lung disease, or bevacizumab-associated severe bleeding.
Cancer October 1, 2018 osimertinib, which might be sensitive to afatinib. 31, 32 We, therefore, speculate that afatinib-bevacizumab combination therapy might be effective after osimertinib failure. Indeed, we are planning a phase 2 trial to evaluate that regimen. The trial will require tissue rebiopsy and liquid biopsy before afatinib-bevacizumab combination therapy so that mechanisms of resistance to osimertinib can be analyzed. Afatinib-bevacizumab combination therapy also demonstrated an acceptable level of safety. There were no treatment-related deaths, interstitial lung disease, bevacizumab-associated severe bleeding, or grade 4 AEs. Afatinib-related AEs such as rash (90.6%) and diarrhea (90.6%) were frequently observed, but those AEs were confirmed with grade 3 or higher severity in only 1 patient (3.1%) each. Paronychia (25%) was the most frequent grade 3 or higher AE. Twenty-three of the patients (72%) who underwent afatinib-bevacizumab therapy were directly switched from other EGFR TKIs. Most of those patients seemed to have remaining paronychia from prior EGFR TKIs. Although the initial dose of afatinib in our study was 30 mg, the remaining paronychia and delayed wound healing caused by bevacizumab might have induced the relatively high incidence of grade 3 or higher paronychia.
To the best of our knowledge, our study is the first study to evaluate the efficacy and safety of afatinib plus bevacizumab after AR to EGFR TKIs. In the first-line setting of EGFR-mutant NSCLC, a phase 1 study of afatinib plus bevacizumab suggested 30 mg of afatinib as a recommended dose of that drug, which was the same as our adopted dose. 33 More has been published on afatinib plus cetuximab 34 or erlotinib plus bevacizumab. The BEVERLY study (NCT02633189), an ongoing phase 3 study in Europe, is comparing erlotinib plus bevacizumab versus erlotinib alone as a first-line treatment for patients with EGFR-mutant NSCLC; T790M+ patients are being excluded. 35 Similar studies include the Chinese ARTEMIS (NCT02759614) and Japanese NEJ026 (UMIN 000017069) phase 3 clinical trials. The randomized phase 2 clinical trial ACCRU RC1126 (NCT01532089) is evaluating erlotinib with or without bevacizumab as a first-line therapy for patients with EGFR-mutant NSCLC. A secondary objective of the ACCRU RC1126 study is to estimate the prevalence of pretreatment T790M and investigate the PFS of patients with and without pretreatment T790M.
Our study has several limitations. First, it had a small sample size and a nonrandomized trial design. To confirm an actual synergistic effect, a randomized trial comparing afatinib with afatinib plus bevacizumab should be conducted. The Japanese LUX-Lung 4 trial of afatinib monotherapy after AR showed an ORR of 8.2% and a median PFS of 4.4 months. 15 EGFR TKI monotherapy rechallenge exhibited an ORR of less than 10% and a median PFS of approximately 4 months. 29, 30 In comparison with those studies, our data suggest a synergistic effect of afatinib-bevacizumab combination therapy. Second, some patients underwent afatinibbevacizumab therapy after a TKI-free interval following prior EGFR TKI failure. TKI sensitivity might have been restored during the TKI-free interval in some of those patients. 30 However, the ORRs and median PFS times of the patients without a TKI-free interval and the patients with a TKI-free interval using cytotoxic regimens were 22% and 11%, respectively, and 5.8 and 7.8 months, respectively, which were similar. Some patients without TKI-free intervals achieved a confirmed partial response, and this indicated that afatinib-bevacizumab combination therapy overcame AR in some patients. It is possible that bevacizumab-naive patients might obtain more clinical benefit from afatinib plus bevacizumab than those with prior exposure to bevacizumab. Unfortunately, our sample size might have been too small to detect a difference in efficacy between bevacizumab-naive and beyond-progression/rechallenged patients by 4 subgroup analyses: T790M+ versus T790M-, Del-19 versus L858R, bevacizumab-naive versus rechallenge/ beyond progression, and no TKI-free interval versus an interval with cytotoxic regimens
In conclusion, afatinib-bevacizumab combination therapy demonstrated clinical efficacy and safety after AR to EGFR TKIs and could be a therapeutic salvage option for T790M-populations. Further studies are warranted to confirm the actual synergistic effects of afatinib and bevacizumab administered in combination.
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